ClinicalTrials.gg
CompletedNCT03319719Updated Oct 1, 2019Results posted

Evaluation of Pain With Belotero® Balance With Integral Lidocaine for Correction of the Nasolabial Folds

An interventional study of Belotero® Balance with integral lidocaine and Belotero® Balance in Correction of Moderate to Severe Nasolabial Folds, sponsored by Merz North America, Inc.. Completed at 3 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2019-10-01.

Sponsored by Merz North America, Inc. (part of Merz Pharma) · Not applicable, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
52
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

Demonstrate the effectiveness of Belotero Balance with lidocaine (Test group) for the reduction of injection-related pain in comparison to Belotero Balance without lidocaine (Control group) for the correction of NLFs.

Identify and describe adverse events (AEs) and serious adverse events (SAEs) during the course of the study. Additionally, common treatment site responses (CTRs) will be assessed.

02

Conditions studied

  • Correction of Moderate to Severe Nasolabial Folds
03

In context

Lead sponsor

Merz North America, Inc. is the lead sponsor of 53 studies on the registry; 2 are open to participants now.

Of its 20 completed or terminated interventional studies of FDA-regulated products, 19 (95%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Has right and left NLF ratings of 2 or 3 (moderate or severe) on the Merz NLF Scale, as determined by the blinded evaluator.
  2. Has the same Merz NLF Scale rating on both NLFs (i.e., symmetrical NLFs).
  3. Is at least 18 years of age.
  4. Understands and accepts the obligation not to receive any other procedures (i.e., dermal fillers, toxin treatments, facial ablative or fractional laser, microderm abrasion, chemical peels, non-invasive skin-tightening [e.g., Ultherapy, Thermage], or surgical procedures) below the orbital rim on the face during study participation.

Exclusion criteria

Exclusion Criteria:

  1. Had prior surgery in the mid- and/or lower-face area, including the nasolabial fold(s), or has a permanent implant or graft in the mid- and/or lower-face area that could interfere with effectiveness assessments. (NOTE: Rhinoplasty is permitted if the procedure was ≥ 12 months prior to study enrollment.)
  2. Has skin or fat atrophy, beyond typical for the subject's age, in the mid- to lower-facial region or has been diagnosed with a connective tissue disorder.
  3. Has unphysiological skin laxity or sun damage, beyond typical for the subject's age, or subject plans to tan during the study period.
  4. Has undergone oral surgery (e.g., orthodontia, extraction, implants) in the past 30 days or plans to receive such surgery during participation in the study.
  5. Has received mid- and/or lower-facial region treatments with porcine-based collagen fillers, Belotero® Volume, JUVÉDERM VOLUMA®, Restylane® Lyft, RADIESSE®, poly L-lactic acid (PLLA), or mesotherapy within the past 24 months and/or with other hyaluronic acid (HA) products within the past 12 months or plans to receive such treatment during participation in the study.
  6. Has ever been treated with fat injections or permanent and/or semi-permanent dermal fillers in the mid- and/or lower-facial region or plans to receive such treatment during participation in the study.
  7. Has received medications or systemic (except intranasal/inhaled steroids) in the past 2 months or plans to receive such treatment during participation in the study.
  8. Has an acute inflammatory process or infection at the injection site (e.g., skin eruptions such as cold sores, cysts, pimples, acne, eczema, hives, streptococcus infections) or history of chronic or recurrent infection or inflammation with the potential to interfere with study results or increase the risk of AEs.
  9. Has a history of allergic/anaphylactic reactions, including to lidocaine or anesthetics of the amide type, hyaluronic acid preparations, gram positive bacterial proteins, or any of the device components.
  10. Has a known bleeding disorder or has received or is planning to receive anti-coagulation, anti-, or thrombolytic medications (e.g., warfarin), anti-inflammatory drugs (oral/injectable corticosteroids or NSAIDs [e.g., aspirin, ibuprofen]), or other substances known to increase coagulation time (e.g., vitamins or herbal supplements, i.e., Vitamin E, garlic, gingko) from 10 days before injection to 3 days after injection.
  11. Has any other medical condition with the potential to interfere with study outcome assessments or compromise subject safety (i.e., increase the risk of adverse events).
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Investigator, Outcomes assessor)
Enrollment
52 participants (actual)

Study arms

  • Experimental
    Belotero® Balance with integral lidocaine

    Belotero® Balance with integral lidocaine will be injected in one of the two NLF (split-face study design: treatment side will be randomized)

    Device: Belotero® Balance with integral lidocaine

  • Active comparator
    Belotero Balance without lidocaine

    Belotero Balance without lidocaine will be injected in one of the two NLF (split-face study design: treatment side will be randomized)

    Device: Belotero® Balance

Interventions

  • DeviceBelotero® Balance with integral lidocaine

    Mode of application: intradermal injection. Maximum treatment volume: 3 mL per nasolabial fold over two Treatment sessions.

    Also known as: Hyaluronic acid dermal filler with lidocaine, single use syringe

  • DeviceBelotero® Balance

    Mode of application: intradermal injection. Maximum treatment volume: 3 mL per nasolabial fold over two Treatment sessions.

    Also known as: Hyaluronic acid dermal filler, single use syringe

06

What researchers measure

Primary outcomes

  1. Mean Pain Using Visual Analog Scale (VAS)

    Pain was assessed using a using a 10 centimeter (cm) VAS. It included 21-numbered circles at 0.5 cm increments, spanning 10 cm total, and was anchored by word descriptors. The VAS scores ranged from 0 (no pain) to 10 (very severe pain).The level of pain was evaluated for each NLF independently immediately upon completion of injection (time zero) on Day 1.

    Time frame: Day 1

Secondary outcomes

  1. Percentage of Responders With Greater Than or Equal to (>=) 1-point Improvement as Evaluated Using Merz NLF Scale at Week 6

    The Merz NLF scale was used to measure the aesthetic effectiveness of the study products. Each NLF was assessed separately. The Merz NLF scale is a 5-grade scale ranging from 0 (no folds) to 4 (very severe folds). Response was defined \>=1-point improvement on the Merz NLF Scale for each NLF compared to baseline.

    Time frame: Week 6

  2. Number of Participants With Treatment Emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs)

    Time frame: Baseline up to Week 6

  3. Number of Participants With Incidence of Any Common Treatment Site Response (CTR) Evaluated Using Participant Diaries

    CTR were evaluated using participant diaries. Participants recorded daily in the diary any pre-defined CTR that occurred. These CTR included swelling, firmness, lumps/bumps, bruising, pain, tenderness upon pressing, redness, discoloration (not redness or bruising), itching, stinging/burning, and numbness.

    Time frame: Baseline up to Week 6

  4. Number of Participants With Incidence of Any CTR by Severity Evaluated Using Participant Diaries

    CTR were evaluated using participant diaries. Participants recorded daily in the diary any pre-defined CTR that occurred. These CTR included swelling, firmness, lumps/bumps, bruising, pain, tenderness upon pressing, redness, discoloration (not redness or bruising), itching, stinging/burning, and numbness.

    Time frame: Baseline up to Week 6

  5. Number of Participants With Incidence of Any CTR by Duration Evaluated Using Participant Diaries

    CTR were evaluated using participant diaries. Participants recorded daily in the diary any pre-defined CTR that occurred. These CTR included swelling, firmness, lumps/bumps, bruising, pain, tenderness upon pressing, redness, discoloration (not redness or bruising), itching, stinging/burning, and numbness.

    Time frame: Baseline up to Week 6

07

Results

Posted Oct 1, 2019

Participant flow

The study was conducted at 3 investigative sites in the United States.

Participant flow — Overall Study
MilestoneBelotero Balance With or Without Lidocaine
Started52
Completed51
Not completed1
Withdrew: Lost to follow-up1

Outcome measures

PrimaryMean Pain Using Visual Analog Scale (VAS)

Pain was assessed using a using a 10 centimeter (cm) VAS. It included 21-numbered circles at 0.5 cm increments, spanning 10 cm total, and was anchored by word descriptors. The VAS scores ranged from 0 (no pain) to 10 (very severe pain).The level of pain was evaluated for each NLF independently immediately upon completion of injection (time zero) on Day 1.

Time frame:
Day 1
Reported as:
Mean · score on a scale
Mean Pain Using Visual Analog Scale (VAS)
score on a scaleTest Product: BBLControl Product: BB
Mean Pain Using Visual Analog Scale (VAS)3.07 ± 1.885.94 ± 2.41
Statistical analysis
  • Test Product: BBL vs Control Product: BB · t-test, 2 sided · p = <0.0001 (p-value from paired two-sided t-tests of no difference between test and control groups.) · Mean difference (net): -2.88 · 95% CI -3.42 to -2.33
SecondaryPercentage of Responders With Greater Than or Equal to (>=) 1-point Improvement as Evaluated Using Merz NLF Scale at Week 6

The Merz NLF scale was used to measure the aesthetic effectiveness of the study products. Each NLF was assessed separately. The Merz NLF scale is a 5-grade scale ranging from 0 (no folds) to 4 (very severe folds). Response was defined \>=1-point improvement on the Merz NLF Scale for each NLF compared to baseline.

Time frame:
Week 6
Reported as:
Number · percentage of participants
Percentage of Responders With Greater Than or Equal to (>=) 1-point Improvement as Evaluated Using Merz NLF Scale at Week 6
percentage of participantsTest Product: BBLControl Product: BB
Percentage of Responders With Greater Than or Equal to (>=) 1-point Improvement as Evaluated Using Merz NLF Scale at Week 651.052.9
SecondaryNumber of Participants With Treatment Emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs)
Time frame:
Baseline up to Week 6
Reported as:
Number · participants
Number of Participants With Treatment Emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs)
participantsBelotero Balance With or Without Lidocaine
TEAEs5
SAEs0
SecondaryNumber of Participants With Incidence of Any Common Treatment Site Response (CTR) Evaluated Using Participant Diaries

CTR were evaluated using participant diaries. Participants recorded daily in the diary any pre-defined CTR that occurred. These CTR included swelling, firmness, lumps/bumps, bruising, pain, tenderness upon pressing, redness, discoloration (not redness or bruising), itching, stinging/burning, and numbness.

Time frame:
Baseline up to Week 6
Reported as:
Number · participants
Number of Participants With Incidence of Any Common Treatment Site Response (CTR) Evaluated Using Participant Diaries
participantsTest Product: BBLControl Product: BB
Number of Participants With Incidence of Any Common Treatment Site Response (CTR) Evaluated Using Participant Diaries4145
SecondaryNumber of Participants With Incidence of Any CTR by Severity Evaluated Using Participant Diaries

CTR were evaluated using participant diaries. Participants recorded daily in the diary any pre-defined CTR that occurred. These CTR included swelling, firmness, lumps/bumps, bruising, pain, tenderness upon pressing, redness, discoloration (not redness or bruising), itching, stinging/burning, and numbness.

Time frame:
Baseline up to Week 6
Reported as:
Number · participants
Number of Participants With Incidence of Any CTR by Severity Evaluated Using Participant Diaries
participantsTest Product: BBLControl Product: BB
Mild2324
Moderate1418
Severe43
SecondaryNumber of Participants With Incidence of Any CTR by Duration Evaluated Using Participant Diaries

CTR were evaluated using participant diaries. Participants recorded daily in the diary any pre-defined CTR that occurred. These CTR included swelling, firmness, lumps/bumps, bruising, pain, tenderness upon pressing, redness, discoloration (not redness or bruising), itching, stinging/burning, and numbness.

Time frame:
Baseline up to Week 6
Reported as:
Number · participants
Number of Participants With Incidence of Any CTR by Duration Evaluated Using Participant Diaries
participantsTest Product: BBLControl Product: BB
1 to 3 days1620
4 to 7 days1414
8 to 17 days89
15 to 30 days32
Greater than (>) 30 days00

Adverse events

Collected over Baseline up to Week 6. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Belotero Balance With or Without Lidocaine0/52 (0%)0/52 (0%)5/52 (9.6%)
Most frequent other events
Most frequent other events
EventBelotero Balance With or Without Lidocaine
HeadacheNervous system disorders2/52
GastroenteritisInfections and infestations1/52
ContusionInjury, poisoning and procedural complications1/52
Skin tightnessSkin and subcutaneous tissue disorders1/52

Baseline characteristics

The safety evaluation set (SES) included all participants who were enrolled into the study, randomized, and received an injection.

Age, Continuous
Age, Continuous(years)Belotero Balance With or Without Lidocaine
Mean58.4 ± 10.2
Sex: Female, Male
Sex: Female, Male(Participants)Belotero Balance With or Without Lidocaine
Female47
Male5
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Belotero Balance With or Without Lidocaine
Hispanic or Latino1
Not Hispanic and not Latino51
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Belotero Balance With or Without Lidocaine
Black or African American16
Caucasian36
Region of Enrollment
Region of Enrollment(Participants)Belotero Balance With or Without Lidocaine
United States52
Fitzpatrick Skin Type
Fitzpatrick Skin Type(Participants)Belotero Balance With or Without Lidocaine
Skin Type I1
Skin Type II20
Skin Type III15
Skin Type IV4
Skin Type V5
Skin Type VI7
08

Study locations

3 sites
  • Center for Dermatology and Dermatology Surgery; Merz Investigational Site #0010170
    Washington, District of Columbia 20037, United States
  • Tennessee Clinical Research Center; Merz Investigational Site #0010097
    Nashville, Tennessee 37215, United States
  • Research Across America (Synexus); Merz Investigational Site #0010125
    Plano, Texas 75093, United States
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Sep 2017 to primary completion in Dec 2017, 2 months.

Results were first posted in Oct 2019, 1 year 9 months after primary completion. A results delay was requested in Nov 2018.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 4, 2017
First posted
Oct 24, 2017
StartActual
Sep 18, 2017
Primary completionActual
Dec 6, 2017
CompletionActual
Dec 6, 2017
Results delay requested
Nov 28, 2018
Results first posted
Oct 1, 2019
Last update
Oct 1, 2019
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 1, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03319719
Responsible party
Sponsor
First posted
Oct 24, 2017
Start date
Sep 18, 2017
Primary completion
Dec 6, 2017
Completion
Dec 6, 2017
Results posted
Oct 1, 2019
Last update
Oct 1, 2019

Study contacts

Peter Kreymerman, MD, FACS
study director · Merz North America, Inc.

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion